Author Interviews, Cancer Research, Immunotherapy / 26.08.2016
Immodulon Aims to Activate Both Arms of Immune System To Fight Broad Range of Cancers
MedicalResearch.com Interview with:
Dr Charles Akle, Chairman and
Dr. Linda Summerton, CEO
Immodulon Therapeutics
Short Hills, NJ 07078 and
London, UK
MedicalResearch.com: What is the background for Immodulon? Would you tell us a little about Dr. Charles Akle?
Response: Immodulon was established in November 2007. The founder and Chairman, Dr Charles Akle, was a Harley Street surgeon and pioneer of keyhole surgery who established Immodulon with the financial support of a former patient. His interest in immunology led him to the potential of cancer immunotherapy long before the term “immuno-oncology” was coined and when skepticism, rather than optimism was the norm.
His ambition from the start was to develop an affordable immunotherapy treatment that would transform the way that cancer is treated in the world today. Since then, Immodulon has become a leading, independent biopharmaceutical company with one of the longest running research projects into how to harness the power of the immune system in treating cancer. It also has its own R&D and manufacturing capability in Lyon, France.
The wider Immodulon senior team has extensive experience of bringing drugs to market and includes Dr James Shannon and Dr Jean Pierre Bizzari.
(more…)
